Reviva Pharmaceuticals Prices $10M Public Offering

Got story updates? Submit your updates here. ›

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the pricing of a $10 million public offering with healthcare-focused institutional investors. The offering includes the sale of 6,666,667 shares of common stock (or equivalents) along with Series G and Series H warrants to purchase additional shares. The company plans to use the proceeds to fund research and development, including a Phase 3 trial for its schizophrenia drug candidate brilaroxazine, as well as for general corporate purposes.

Why it matters

This funding will allow Reviva to advance its pipeline of novel therapies targeting central nervous system, inflammatory, and cardiometabolic diseases - areas of significant unmet medical need. The public offering demonstrates investor confidence in the company's drug candidates and development strategy.

The details

The shares and warrants are being offered at a combined price of $1.50 per unit. The Series G Warrants have a $1.50 exercise price and a 5-year term, while the Series H Warrants have a 12-month term. The offering is expected to close on or around March 20, 2026, subject to customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent.

• The offering is expected to close on or about March 20, 2026.

What’s next

The company plans to use the net proceeds from the offering, along with its existing cash, to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia.